San Diego-based mostly Viking Therapeutics marked alone as a significant competitor while in the weight loss drug market in February soon after revealing promising info from a mid-phase demo of experimental drug VK2735, which advised it rivaled—and outperformed—Novo and Lilly drugs when given being a weekly injection and in March the company un